Biostem Technologies (BSEM) Conference presentation summary

Corporate overview and market opportunity

• Commercial-stage medtech company specializing in placental tissue allografts for advanced wound care, with positive revenue and adjusted EBITDA through Q3 2025.

• Market capitalization of $84M, share price at $5.00 as of January 2026, and approximately 60 employees.

• Addresses a $1B+ advanced wound care market, with over 7 million chronic wound patients in the US and significant growth in diabetes and aging populations.

• Expanding access to hospital, VA, and burn care sites could double market opportunity, targeting both private and public healthcare sectors.

• State-of-the-art, scalable manufacturing facility with capacity to process up to 100,000 sq cm per month.

Product and technology highlights

• Proprietary BioRetain® technology platform clinically proven to outperform competitors in wound closure rates and efficiency.

• BioRetain® preserves natural tissue properties, offering higher levels of anti-inflammatory cytokines, growth factors, and extracellular matrix components.

• Technology supported by 58 issued patents and 68 pending, with a four-year shelf-stable product.

• Advanced, vertically integrated manufacturing accredited by AATB and CGTP, with 6,100 sq ft of dedicated space.

Financial performance and strategy

• YTD revenue through Q3 2025 reached $37.4M, with adjusted EBITDA of $13.0M and $27.2M in cash.

• Q3 2025 saw a 41% growth in volume after pricing adjustments, despite a decline in ASP ranking.

• Multi-channel commercial strategy includes expanding direct sales, regional distributors, and national partnerships.

• Focused on leveraging GPO contracts and expanding into new sites of care to diversify and grow revenue.